Study of XL820 in Adults With Solid Tumors

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00129571

Enrollment

Unknown

Registered

2005-08-12

Start date

2005-08-31

Completion date

Unknown

Last updated

2008-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.

Interventions

DRUGXL820

Study design

Allocation

NON_RANDOMIZED

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Advanced solid tumor * Cancer for which standard therapies do not exist or are no longer effective * Life expectancy of \> 3 months * Adequate bone marrow, liver, and kidney function * Willing to use accepted method of contraception during the course of the study * Negative pregnancy test (females) * Written informed consent

Exclusion criteria

* Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy) * Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment * Investigational drug within 30 days of the start of treatment * Subjects with known brain metastasis * Uncontrolled medical disorder such as infection or cardiovascular disease * Subjects known to be HIV positive * Pregnant or breastfeeding women

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026